Filter Results:
(611)
Show Results For
- All HBS Web
(1,024)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (397)
Show Results For
- All HBS Web
(1,024)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (397)
Sort by
- 05 Jul 2006
- Research & Ideas
The Accidental Innovator
for a new ulcer drug and discover one in a surprising way, that's not quite as amazing as if you are looking for a new ulcer drug and discover instead a new artificial sweetener (this is how Aspartame,... View Details
Keywords: by Sarah Jane Gilbert
- 22 Aug 2005
- Research & Ideas
The Hard Work of Failure Analysis
the hospital quickly followed their example, finding the idea compelling and practical. In the pharmaceutical industry, about 90 percent of newly developed drugs fail in the experimental stage, and thus drug... View Details
Keywords: by Amy Edmondson & Mark D. Cannon
- 21 Feb 2023
- Research & Ideas
What's Missing from the Racial Equity Dialogue?
Stanford University’s Center for Advanced Study in the Behavioral Sciences. He studies the relationship among incarceration, employment, and entrepreneurship. You Might Also Like: The Color of Private Equity: Quantifying the Bias Black Investors Face Buy-In from Black... View Details
Keywords: by Danielle Kost
- 25 Aug 2003
- Research & Ideas
Why IT Does Matter
Radio-frequency identification devices for grocery stores, smart cards, and automated ordering systems for hospital physicians are all examples of new process targets that technologies will soon address. In the more distant future we will see the improved creation of... View Details
Keywords: by F. Warren McFarlan & Richard L. Nolan
- 20 Oct 2011
- Research & Ideas
Getting the Marketing Mix Right
they studied the three primary ways these drugs were marketed by Pfizer, Merk, Bristol-Myers Squibb, and AstraZeneca: "detailing," in which drug firm representatives personally visit physicians to... View Details
Keywords: by Dina Gerdeman
- 08 Feb 2000
- Research & Ideas
Building Effective R&D Capabilities Abroad
to commercialize its R&D more effectively in foreign markets. Until then, Eli Lilly had operated one home-base-augmenting laboratory site abroad and some small sites in industrialized countries for clinical testing and drug approval... View Details
Keywords: by Walter Kuemmerle
- 17 Sep 2021
- Research & Ideas
The Trial of Elizabeth Holmes: Visionary, Criminal, or Both?
jail. Notably, that’s even when they are engaged in the kinds of fraudulent behavior we send people to jail for. They think the people that go to jail are the people that didn’t go to the great schools, that weren’t the Stanford dropouts. It’s the guy on the street... View Details
- 23 May 2023
- Research & Ideas
Lessons on Life, Graffiti, and Value: 'It's in That Darkness That You Can Actually Develop and Evolve'
said. Graffiti was also a form of escape. In the 1980s and ’90s, gang violence and drugs were rampant in Los Angeles. For young people seeking a different path, graffiti crews offered an identity that was of the streets but not confined... View Details
Keywords: by Christina Pazzanese, Harvard Gazette
- 15 Nov 2018
- Book
Can the Global Food Industry Overcome Public Distrust?
JamesBrey Food is the largest segment of the global economy. It is also widely recognized as more critical for human health than any pharmaceutical drug on the planet. But significant changes in the industry are making people lose trust in many institutions involved in... View Details
- 2023
- Article
Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance
By: Alexander O. Everhart, Soumya Sen, Ariel D. Stern, Yi Zhu and Pinar Karaca-Mandic
Importance: Most regulated medical devices enter the U.S. market via the 510(k) regulatory submission pathway, wherein manufacturers demonstrate that applicant devices are “substantially equivalent” to 1 or more “predicate” devices (legally marketed medical devices... View Details
Everhart, Alexander O., Soumya Sen, Ariel D. Stern, Yi Zhu, and Pinar Karaca-Mandic. "Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance." JAMA, the Journal of the American Medical Association 329, no. 2 (2023): 144–156.
- 29 Jan 2021
- Op-Ed
How Influencers, Celebrities, and FOMO Can Win Over Vaccine Skeptics
of the much harsher consequences. India’s fight against HIV provides a good example to follow: Cipla, the maker of generic drugs, provided a simple message: Its low-priced drugs treated life-threatening conditions, and this message was... View Details
- Research Summary
Clinical Trials as a setting for Health Policy and Management Research
The clinical trial marketplace is in flux. A decade ago, pharmaceutical firms almost exclusively conducted the study of their novel drug compounds within major academic medical centers. But today, industry-sponsored clinical trials are increasingly using community... View Details
- 19 Sep 2016
- Research & Ideas
Why Isn't Business Research More Relevant to Business Practitioners?
disciplines, where academic research is leading to the development of a second skin that could improve drug delivery or alerting farmers and scientists on how to reduce nitrous oxide emissions from agricultural farming. Harvard Business... View Details
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
coming of age of biotechnology. The disappearance of "blockbuster" drugs could create new management challenges for pharmaceutical companies. — Gary Pisano The prospect is exhilarating, but the road to this brave new biotech... View Details
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
as 1994: That year was known among insiders as "The Year of the Placebo." What The Data Says The good news: One hundred thirty drugs can be traced to biotech, said Pisano. (For purposes of discussion during his presentation, he... View Details
- 10 Nov 2020
- Sharpening Your Skills
Research News and Tips: Innovating Across Time Zones
Dany Bahar, Prithwiraj Choudhury, and Britta Glennon. Drugs approved in December are associated with more adverse effects New research reveals that drug approvals surge in the US in December, at month-ends,... View Details
Keywords: by Sean Silverthorne
- 23 Mar 2003
- Research & Ideas
AIDS in Africa—What’s the Solution?
5th Annual Africa Business Conference at Harvard Business School on March 8. Much of the debate over AIDS in Africa has surrounded the high cost of the drugs that have turned the deadly disease into one that patients in the West can now... View Details
Keywords: by Julie Jette
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
Now that scientists have mapped the human gene, can drug makers map a road to unlimited riches? For John Lechleiter, Executive Vice President of Eli Lilly and Company's Pharmaceutical Products and Corporate Development, there remain more... View Details
Keywords: by Sean Silverthorne
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
pharma," said HBS professor Regina Herzlinger, moderating a panel discussion titled "Pharma and Biotech—Where does Europe Stand in the World?" The discussion was held at the conference on November 22. At the start of the 1990s, the U.S. and European... View Details
- 30 Mar 2010
- First Look
First Look: March 30
regulatory objections were debated and tensions rose between U.S. and EC regulators. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/310086-PDF-ENG Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and... View Details
Keywords: Sean Silverthorne